SoFi CEO enters prepaid forward contract on 1.5 million shares
LONDON - EKF Diagnostics Holdings plc (AIM:EKF), a global diagnostics company, has completed a share buyback, purchasing 177,279 of its ordinary shares at a price of 21 pence per share, the company announced on Monday. The shares acquired on May 2, 2025, will be held in treasury.
The transaction took place on the London Stock Exchange (LON:LSEG)’s AIM market, with two separate trades executed; 125,000 shares were bought at 13:06:23 and the remaining 52,279 shares at 16:17:49.
Following the repurchase, EKF’s total issued share capital consists of 454,930,564 ordinary shares, each with one voting right. With 3,767,887 ordinary shares now held in treasury, the total number of voting rights in the company has been reduced to 451,162,677. This figure is relevant for shareholders when determining their need to disclose changes in their shareholding under the FCA’s Disclosure Guidance and Transparency Rules.
In connection with the buyback, a portion of the shares, specifically 52,279 ordinary shares, was acquired from investment entities managed by Harwood. The transaction included 17,427 shares from Oryx International Growth Fund Limited and 34,852 shares from North Atlantic Smaller Companies Investment Trust PLC, both associated with Non-Executive Director Christopher Mills. This move was intended to maintain Mr. Mills’ aggregate indirect beneficial interest in EKF at approximately the same level, ensuring it does not exceed 30% of the total voting rights.
As a result of the transaction, Mr. Mills’ indirect interest in EKF now stands at 133,043,305 ordinary shares. The share buyback and the related PDMR dealing are reported in accordance with the Market Abuse Regulation.
This share buyback operation is part of EKF’s strategy to manage its capital efficiently. The company, headquartered in Penarth, operates manufacturing sites in the US and Germany and distributes its products to over 120 countries worldwide. EKF specializes in point-of-care analyzers for hematology and diabetes, as well as providing life sciences services.
The information reported is based on a press release statement by EKF Diagnostics Holdings plc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.